Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing

Current Oncology Reports, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 5, 2025

Language: Английский

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Antibody-drug conjugates (ADCs) are a transformative approach in breast cancer therapy, offering targeted treatment with reduced toxicity by selectively delivering cytotoxic agents to cells. While ADCs like trastuzumab emtansine (T-DM1), deruxtecan (T-DXd), and sacituzumab govitecan have shown significant efficacy, resistance mechanisms such as antigen loss, impaired internalization, efflux of payloads challenge their effectiveness. This review discusses these explores advanced strategies overcome them, including innovations linker chemistry, multi-antigen targeting, biomarker-driven personalization. Additionally, therapeutic sequencing - determining the optimal order other treatments chemotherapy, endocrine immunotherapy is examined crucial maximize ADC efficacy manage resistance. Evidence-based strategies, particularly for human epidermal growth factor receptor 2 (HER2)-positive triple-negative (TNBC), supported clinical trials demonstrating benefits both early-stage metastatic settings. The potential combination therapies, immune checkpoint inhibitors (ICIs), further highlights evolving landscape treatment. As technology advances, personalized approaches integrating biomarkers optimized protocols offer promising avenues enhance outcomes combat cancer.

Language: Английский

Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 4104 - 4104

Published: Dec. 7, 2024

HER2-positive breast cancer (HER2

Language: Английский